Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
212.3 USD | +15.72% | +19.44% | +24.18% |
05:37pm | KeyBanc Adjusts Price Target on ResMed to $238 From $227 | MT |
05:04pm | ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.18% | 26.94B | B+ | ||
+7.87% | 218B | B | ||
+6.45% | 182B | B- | ||
+11.16% | 132B | B- | ||
+26.68% | 108B | A- | ||
+13.21% | 52.98B | B+ | ||
-1.89% | 47.59B | B+ | ||
-0.83% | 39.96B | A | ||
+11.02% | 39.22B | - | ||
-11.89% | 19.28B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RMD Stock
- Ratings ResMed, Inc.